**2.2.1 Mifamurtide (MTP-PE)**

In pyrogenicity test in rabbits, pyrogenic activity of Mifamurtide i.v. was comparable to that of MDP. In several studies with cancer patients refractory to standard therapy, infused with liposomal Mifamurtide at a dose range of 0.01 – 1.8 mg/m2/dose, dose-dependent fever (in common about 70% of patients) and rigor (about 50% of patients) were the most prominent from a number of acute systemic toxicities (Creaven et al., 1990).

Mifamurtide was also assayed as an additional immunomodulator in an MF59-adjuvanted influenza virus vaccine (Keitel et al., 1993) and HIV-1 vaccine (Keefer et al., 1996); systemic symptoms including fever, chill, and nausea made these vaccines unsuitable for clinical use. Today, the main interest lies in clinical trials for liposomal Mifamurtide as a component of three-drug chemotherapy of osteosarcoma (Anderson P.M, 2006; Anderson et al., 2010).
